| Drug Name |
Doxazosin |
| Drug ID |
BADD_D00718 |
| Description |
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] |
| Indications and Usage |
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637] |
| Marketing Status |
approved |
| ATC Code |
C02CA04 |
| DrugBank ID |
DB00590
|
| KEGG ID |
D07874
|
| MeSH ID |
D017292
|
| PubChem ID |
3157
|
| TTD Drug ID |
D03MIR
|
| NDC Product Code |
16729-213; 43063-739; 50268-224; 58657-820; 58657-821; 63629-7891; 0049-2040; 0049-2614; 70518-3667; 71335-0309; 71610-043; 42291-258; 50090-0734; 51655-476; 55154-7996; 58657-823; 0049-2080; 68084-836; 68084-851; 68788-8422; 70771-1114; 71205-690; 59762-2420; 60505-0094; 66267-377; 68071-3298; 68382-784; 68788-8412; 58657-822; 68382-783; 70518-2183; 16729-211; 42291-259; 42291-260; 0049-2410; 70934-728; 71335-0002; 23155-095; 50090-2153; 50090-5773; 60505-0093; 68084-862; 68382-786; 68788-7328; 0904-5523; 0904-5524; 23155-093; 50090-0701; 50090-0706; 50268-225; 60505-0095; 70518-1560; 70518-1804; 70771-1112; 70934-921; 16729-414; 23155-094; 50090-3927; 50090-5540; 59762-2440; 60505-0096; 0049-2716; 68382-785; 68788-7149; 70771-1113; 70771-1115; 23155-092; 51655-109; 59762-2480; 71610-153; 72189-117; 16729-415; 50090-0704; 50268-223; 0049-2512; 71335-0349; 71610-160; 71610-628; 0904-5522; 50268-222; 59762-2410 |
| UNII |
NW1291F1W8
|
| Synonyms |
Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274 |
